Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 11/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8219081 | 0.91 | NAMPT (0.43) | NAMPTPIK3CAMTORKMT2ADDX3X | |
| SCHEMBL8215290 | 0.89 | PIK3CD (0.46) | NAMPTPIK3CAMTORPIK3CGKMT2A | |
| SCHEMBL8219083 | 0.86 | NAMPT (0.40) | NAMPTPIK3CAMTORPIK3CGKMT2A | |
| SCHEMBL11925970 | 0.85 | PIK3CA (0.50) | NAMPTPIK3CAMTORPIK3CGATM | |
| SCHEMBL8214019 | 0.85 | ATM (0.45) | PIK3CAMTORPIK3CGATMPOLB | |
| SCHEMBL8212594 | 0.84 | PIK3CA (0.49) | PIK3CAMTORPIK3CGATMPOLB | |
| SCHEMBL11926888 | 0.84 | KIF11 (0.43) | NAMPT | |
| SCHEMBL8215180 | 0.84 | NAMPT (0.46) | NAMPTPIK3CAMTORPIK3CGATM | |
| SCHEMBL8214032 | 0.83 | ATM (0.45) | NAMPTPIK3CAMTORPIK3CGATM | |
| SCHEMBL3607952 | 0.82 | PIK3CA (0.65) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |